ArticleCPT: pharmacometrics & systems pharmacology2025
Incorporating Multiple Imputation Into Tanezumab Dose-Response Modeling of WOMAC Pain CFB Across Six Randomized Placebo-Controlled Phase 3 Trials.
Martin Boucher et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.